MedTrace Logo

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

NCT01456416 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2013-04-04

No results posted yet for this study

Summary

The incidence of autoimmune conditions is at least 2-3 times higher in Multiple Sclerosis population than in general population. These MS patients category response unfavorably to the Interferon. The investigators suggest that autoimmune co morbidity can serve as a biological marker predicting good response to GA.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    collaborator INDUSTRY

  • University of Southern California

    lead OTHER

Principal Investigators

  • Regina Berkovich, M.D.Ph.D · LAC+USC

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01456416 on ClinicalTrials.gov